GlassScriptPhysician profile
Claude Demosthene Simon
NPI 1811982424
$16,990.50
in general payments reported to CMS, 2019-2025
31 companies · $4,148 in 2025
The $4,148 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,621 · 2020: $1,274 · 2021: $2,791 · 2022: $926 · 2023: $574 · 2024: $657 · 2025: $4,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,409 · Travel and Lodging: $1,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,408.54 |
| Travel and Lodging | $1,970.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,264.28 | 2019-2020 | |
| Philips North America LLC | $2,545.26 | 2019-2025 | Coronary Other |
| Shockwave Medical, INC | $1,642.61 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $1,541.83 | 2019-2025 | |
| Terumo Medical Corporation | $1,528.70 | 2021-2022 | |
| Esperion Therapeutics, INC. | $895.43 | 2020-2025 | Nexletol |
| Abbott Laboratories | $864.46 | 2019-2025 | Xience Skypoint, Pressurewire |
| Boston Scientific Corporation | $861.85 | 2019-2025 | 2cm Peripheral Cutting Balloon, Varithena Administration Pack |
| Astrazeneca Pharmaceuticals LP | $806.95 | 2019-2025 | Lokelma, Farxiga |
| Cardiovascular Systems INC. | $792.63 | 2019-2023 | Diamondback Peripheral |
| Angiodynamics, INC. | $311.14 | 2022 | |
| Medtronic, INC. | $310.24 | 2021-2025 | Venaseal, Closurefast |
| E.R. Squibb & Sons, L.L.C. | $294.99 | 2020-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $183.42 | 2021-2023 | |
| Novo Nordisk INC | $153.16 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $144.60 | 2023-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $127.14 | 2019 | |
| Merck Sharp & Dohme LLC | $118.69 | 2022-2025 | Verquvo |
| Bard Peripheral Vascular, INC. | $109.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $70.17 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.30 | 2021 | |
| Lilly USA, LLC | $55.76 | 2023-2024 | Mounjaro, Zepbound |
| Bridgebio Pharma, INC. | $50.99 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $49.58 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.07 | 2024 | Jardiance |
| Penumbra, INC. | $39.45 | 2020-2024 | Indigo System |
| Kestra Medical Technology Services, INC. | $28.45 | 2024 | Assure Wcd |
| Pfizer INC. | $26.55 | 2025 | |
| Cardiva Medical, INC. | $24.17 | 2019 | |
| Scpharmaceuticals INC. | $23.99 | 2025 | |
| Chiesi USA, INC. | $15.92 | 2025 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.